Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential ...

No use of a controller medication before starting an LABA 6,043 (60.4) 760 (63.2) 268 (34.9) 10,635 (78.9) Use of a controller medication before starting an LABA 3,969 (39.6) 443 (36.8 ...

multicenter trial among 2,516 persons age 12 years and older with mild asthma that was uncontrolled despite treatment with a short-acting beta-2 agonist with or without a low-dose inhaled ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

The Salford study recruited a total of 4,233 patients who were taking inhaled corticosteroid (ICS) with or without a long acting beta 2-agonist (LABA) were randomised to receive either FF/VI or to ...

The combination of the inhaled corticosteroid (budesonide) and short-acting beta-2 adrenergic agonist (albuterol sulfate) is FDA approved for as-needed use in adults with asthma based on the ...

The AERIFY-2 phase 3 study did not meet the same primary ... to double therapy (inhaled corticosteroid [ICS] plus long-acting beta2-agonist [LABA] or long-acting muscarinic antagonist [LAMA ...

INBRIJA, a dopamine replacement therapy for off periods in Parkinson's disease, holds significant market potential due to its ability to provide rapid relief from motor symptoms. With the increasing ...

The drug, which combines an inhaled corticosteroid (ICS) with a long-acting beta 2 agonist, was co-developed with Innoviva. Mike Aguiar, CEO of Innoviva, said “We believe the results of this ...

once-daily inhaled placebo (n=4111), long-acting beta 2-agonist (vilanterol (VI) 25 µg; n=4118), corticosteroid (fluticasone furoate (FF) 100 µg; n=4135) and combination therapy (FF/VI; n=4121).